Cardiff Oncology, Inc.
Status: Publicly traded
Direct answer
Cardiff Oncology, Inc. is publicly traded on NASDAQ under the ticker CRDF.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic...
Can you invest in Cardiff Oncology, Inc.?
Yes. Cardiff Oncology, Inc. trades publicly on NASDAQ as CRDF.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Cardiff Oncology, Inc.
Detailed equity research is provided by MarketSnap.